Clinical trials: Allogeneic Stem Cell Transplantation
Lung Neoplasm, Carcinoma, Bronchogenic
Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
In this Phase II clinical trial the investigators will use four human non-small cell lung cancer cell lines that have been previously established in tissue culture laboratory.
- Trial name
- NCT01058785
- Testing
- Lucanix
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- NovaRx Corporation
Degenerative Disc Disease
Trinity Evolution in Anterior Cervical Disectomy and Fusion (ACDF)
The purpose of this study is to utilize Trinity Evolution in conjunction with an interbody spacer and supplemental anterior fixation of the surgeon's choice and to follow the patients to measure the clinical outcomes and rate of…
- Trial name
- NCT00951938
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- Orthofix Inc.
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
The purpose of this study is to determine whether a one-time injection of allogeneic mesenchymal bone marrow cells is safe and beneficial in the treatment of photodamage on the face.
- Trial name
- NCT01771679
- Testing
- Allogeneic Mesenchymal Bone Marrow Cells
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Stemedica Cell Technologies, Inc.
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Acute Graft Versus Host Disease
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
The study was an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days…
- Trial name
- NCT03491215
- Testing
- Ruxolitinib
- Where
- 19 sites in Belgium, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins…
- Trial name
- NCT01909752
- Testing
- Cyclophosphamide, DRibble vaccine, Imiquimod
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UbiVac
Astrocytoma, Grade IV, Glioblastoma
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
A Phase 1/2a Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001 in Combination with Recombinant Human Interleukin-2 in Adults with Recurrent Resection Eligible IDH1 wild-type Glioblastoma.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Trial name
- CYNK001GBM02 (NCT05218408)
- Testing
- CYNK-001 systemic and Intra cavity administration
- Sponsor
- Celularity Incorporated
Acute Myeloid Leukemia, Myelodysplastic Syndromes
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
This is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with Acute Myeloid Leukemia (AML), or Myelodysplastic Syndromes (MDS)/AML, with either refractory or relapsed…
- Trial name
- ACHIEVE (NCT05358808)
- Testing
- TCB008
- Where
- 6 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- TC Biopharm
Gingival Recession
Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration
The purpose of this study is to evaluate Gintuit as a safe and effective alternative to palatal tissue in the treatment of subjects (with recession-type defects) who have an insufficient zone of attached gingiva associated with…
- Trial name
- NCT00587834
- Testing
- Gintuit, Autologous palatal tissue
- Where
- 4 sites in United States
- Volunteers
- 96 people
- Sponsor
- Organogenesis
Kidney Tubular Necrosis, Acute
Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery
The purpose of this trial is to determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant Acute Kidney Injury (AKI) after undergoing on-pump cardiac…
- Trial name
- NCT00733876
- Testing
- Multipotent Stromal Cells, Administration of MSC
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- AlloCure Inc.
Acute Ischemic Stroke
A Study of B2065 in Patients With Acute Ischemic Stroke
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke.
- Trial name
- NCT07371624
- Testing
- B2065
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Crohn's Disease
A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease
This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.
- Trial name
- NCT02580617
- Testing
- ALLO-ASC
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Anterogen Co., Ltd.
CRC (Colorectal Cancer), Metastatic Colorectal Cancer
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer.
- Trial name
- Wondercel-UWD1 (NCT06653010)
- Testing
- Universal CAR-T cells injection for treating mCRC
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Fecal Microbiota Transplantation
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
Patients who have a gastrointestinal acute Graft versus host disease (GVHD) received a first-line standard treatment of corticosteroids. For patients who do not respond or progress after an initial response have a high mortality.
- Trial name
- HERACLES (NCT03359980)
- Testing
- fecal microbiota transfer
- Where
- 16 sites in France, Italy and 1 more
- Volunteers
- 24 people
- Sponsor
- MaaT Pharma
Localized Adverse Reaction to Administration of Drug
Intralymphatic eASC Administration in Healthy Volunteers
The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)
- Trial name
- NCT01743222
- Testing
- eASC
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tigenix S.A.U.
Peripheral Arterial Occlusive Disease
Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one…
- Trial name
- NCT03339973
- Testing
- allo-APZ2-PAOD
- Where
- 18 sites in Austria, Czechia and 3 more
- Volunteers
- 24 people
- Sponsor
- RHEACELL GmbH & Co. KG
Cytomegalovirus Infection
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks.
- Trial name
- NCT00942305
- Testing
- Brincidofovir
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals
Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell (ULSC) product performs when treating Dermatomyositis/Polymyositis (DM/PM), also known as idiopathic inflammatory myopathy (IIM) in…
- Trial name
- IIMPACT (NCT07160205)
- Testing
- ULSC (1.5 x 10^8 cells/dose)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Restem, LLC.
Advanced Heart Failure, Ischemic Heart Failure
HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery
This clinical study will evaluate the safety and tolerability of HiCM-188, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy, in adults with advanced heart failure who are undergoing…
- Trial name
- NCT07646210
- Testing
- HiCM-188 Cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HELP Therapeutics Co., Ltd.